| Identification | Back Directory | [Name]
AMMONIUM TRICHLORO[1,2-ETHANEDIOLATO-O,O']-TELLURATE | [CAS]
106566-58-9 | [Synonyms]
AS 101
CTK8E8213
RT-011323
Interleukin Related
CTK8E8213;RT-011323
AMMONIUM TRICHLORO[1,2-ETHANEDIOLATO-O,O']-TELLURATE | [Molecular Formula]
C2H4Cl3O2Te.H4N | [MDL Number]
MFCD01682758 | [MOL File]
106566-58-9.mol | [Molecular Weight]
312.049 |
| Hazard Information | Back Directory | [Uses]
AS 101 inhibits AKT activity in leukemic cells and has bee shown to favorably affect renal pathologies in various animal models. AS 101 inhibition of the AKT downstream pathway by AS101 has clinical potential in alleviating the progression of diabetic nephropathy. | [Biological Activity]
Immunomodulator; inhibits IL-10 synthesis and potentiates IL-1 α , IL-2 and TNF- α release. | [in vivo]
Ossirene (AS101; 0.5 mg/kg/day; IP; 25 days) sensitizes GBM tumors to paclitaxel via inhibition of IL-10, resulting in increased survival[2].
| Animal Model: | SCID mice with GBM cells[2] | | Dosage: | 0.5 mg/kg | | Administration: | IP; daily; 25 days | | Result: | Significantly increased survival of GBM tumor-bearing mice.
|
| [IC 50]
IL-1β; IL-6; IL-8; IL-10; Caspase-1 | [storage]
Store at -20°C | [References]
[1] kalechman y, sredni b, weinstein t, et al. production of the novel mesangial autocrine growth factors gdnf and il-10 is regulated by the immunomodulator as101[j]. journal of the american society of nephrology, 2003, 14(3): 620-630.
[2] kalechman y, gafter u, weinstein t, et al. inhibition of interleukin-10 by the immunomodulator as101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis association with dephosphorylation of stat3[j]. journal of biological chemistry, 2004, 279(23): 24724-24732.
[3] sredni b, caspi r r, klein a, et al. a new immunomodulating compound (as-101) with potential therapeutic application[j]. nature, 1987, 330(6144): 173-176.
[4] sredni b, albeck m, tichler t, et al. bone marrow-sparing and prevention of alopecia by as101 in non-small-cell lung cancer patients treated with carboplatin and etoposide[j]. journal of clinical oncology, 1995, 13(9): 2342-2353.
[5] kalechman y, gafter u, gal r, et al. anti-il-10 therapeutic strategy using the immunomodulator as101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention[j]. the journal of immunology, 2002, 169(1): 384-392. |
|
|